Abstract: Objective To study the clinical efficacy and safety of Tulobuterol patch (Amiaid) in the treatment of bronchiolitis in infants. Methods The 103 infants with bronchiolitis in Department of Pediatrics of the First Affiliated Hospital of Bengbu Medical College from November 2017 to February 2018 were enrolled into this study, and divided into treatment group (n=52) and control group (n=51) according to the date of the doctor's day. The patients in both groups received atomized inhalation of Budesonide suspension and Reduning injection, and sensitive antibiotics were administrated if combined with bacterial infections. When necessary, oxygen therapy, sedation, controlling cough, dilution phlegm and other symptomatic support treatment were performed. The children in the treatment group received additional tulobuterol patch, while the children in the control group received additional atomized inhalation of Albuterol sulfate inhalation solution. The improvement of clinical performance, hospitalization time and the incidence of severe adverse reactions were compared between the two groups before and after the treatment. Results The effective rate in the treatment group was significantly higher than that in the control group (P < 0.05), and the difference was statistically significant. The time for improvement of the cough, the duration of asthma, the loss of asthma in the lungs, and the length of hospital stay in the treatment group were significantly shorter those in the control group, the difference was statistically significant (all P < 0.05). The incidence and severity of adverse reactions in the treatment group was lower than those in the control group, and the difference was statistically significant (P < 0.05). Conclusion The effect of Tulobuterol patch on the bronchiolitis of infants is significant, with highly secure, convenient and few adverse reaction, and it is worth spreading in clinical practice.